Both human and animal studies reported inconsistent BP response to acute administration but showed hypotensive effect of chronic administration of GLP-1/ GLP-1 RAs
Over the last decade, although the prescription of GLP-1 RAs has increased slightly, overall usage remains low compared with other glucose-lowering medications, such as metformin, sulfonylureas and dipeptidyl peptidase 4 inhibitors (DPP4i), regardless of CV disease status [30,31,32,33]
No, GLP-1 receptor agonists are not licensed by the MHRA specifically for treating inflammatory conditions
Its primary functions include: Stimulating Insulin Release: GLP-1 tells the pancreas to release insulin, which helps your cells absorb glucose from the bloodstream, thereby lowering blood sugar levels after a meal
A., Yu, O